Abbott

In Brief This Week: Singular Genomics, T2 Biosystems, Revvity, Agilent Technologies, Danaher, More

News items for the week of Feb. 17, 2025.

Abbott Receives FDA Clearance for Self-Collected STI Molecular Test

The device is intended for self-collection of samples in home settings and testing in a clinical laboratory.

Abbott Q4 Diagnostics Revenues up 4 Percent, Excluding COVID-19 Tests

The firm's Q4 2024 overall revenues were up 7 percent and full-year 2024 revenues were up 5 percent.

In Brief This Week: Abbott, Thermo Fisher Scientific, Personalis, Illumina, NHS Wales, More

News items for the week of Nov. 4, 2024.

Abbott Q3 Diagnostics Revenues Down 2 Percent

The firm's total revenues increased 5 percent year over year, leading it to raise the midpoint of its full-year EPS guidance.

Oct 3, 2024

WHO Approves Abbott Molecular Mpox Assay

Sep 20, 2024

In Brief This Week: Hologic, Illumina, LGC Biosearch, Agilent, Abbott, Eurofins, Centogene, More

Jul 18, 2024

Abbott Q2 Dx Revenues Fall 5 Percent, Firm Raises Full-Year Guidance

Jun 14, 2024

In Brief This Week: Pacific Biosciences, Singleron Biotechnologies, Abbott, Enzo Biochem, Oligo Factory

Apr 17, 2024

Abbott Diagnostics Q1 Revenues Down 18 Percent, Total Revenues up 2 Percent

Jan 24, 2024

2023 a 'Transition Year' for Abbott as Full-Year Non-COVID Revenues Rise 12 Percent
Premium

Jan 10, 2024

JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Illumina, Oxford Nanopore, Natera, More

Nov 2, 2023

Abbott Molecular HPV Test Nabs FDA Approval

Oct 25, 2023

Abbott PCR Test Gets FDA Approval as CDx for Servier's Tibsovo for Rare Blood Cancer

Oct 18, 2023

Abbott Q3 Diagnostics Revenues Fall 33 Percent on Lower COVID-19 Testing

Sep 22, 2023

In Brief This Week: DermTech, Cerca Biotech, Colossal Biosciences, Biocept, Abbott, More

Jul 20, 2023

Abbott Emphasizes Base Business Growth as Q2 Dx Revenues Drop 46 Percent

Apr 21, 2023

In Brief This Week: UC Berkeley, Biocept, Biocartis, Angle, Twist Bioscience, More

Apr 19, 2023

Abbott Alinity Sales up as Normal Hospital Purchasing Patterns Return; Dx Q1 Revs Down 49 Percent
Premium

Mar 6, 2023

As Pandemic Wanes, Firms That Rode COVID-19 Testing Wave Struggle for Solid Footing
Premium

Feb 24, 2023

In Brief This Week: Personalis, Biocartis, Opko Health, Berkeley Lights, More

Feb 10, 2023

In Brief This Week: Meridian Bioscience, SQI Diagnostics, Applied DNA, Abbott, Danaher, More

Jan 25, 2023

Abbott Q4 Diagnostics Revenues Fall 26 Percent on Declining COVID-19 Sales

Jan 11, 2023

JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Agilent, Roche, Seer, More

Oct 19, 2022

Abbott

In Brief This Week: Singular Genomics, T2 Biosystems, Revvity, Agilent Technologies, Danaher, More

Abbott Receives FDA Clearance for Self-Collected STI Molecular Test

Abbott Q4 Diagnostics Revenues up 4 Percent, Excluding COVID-19 Tests

In Brief This Week: Abbott, Thermo Fisher Scientific, Personalis, Illumina, NHS Wales, More

Abbott Q3 Diagnostics Revenues Down 2 Percent

WHO Approves Abbott Molecular Mpox Assay

In Brief This Week: Hologic, Illumina, LGC Biosearch, Agilent, Abbott, Eurofins, Centogene, More

Abbott Q2 Dx Revenues Fall 5 Percent, Firm Raises Full-Year Guidance

In Brief This Week: Pacific Biosciences, Singleron Biotechnologies, Abbott, Enzo Biochem, Oligo Factory

Abbott Diagnostics Q1 Revenues Down 18 Percent, Total Revenues up 2 Percent

2023 a 'Transition Year' for Abbott as Full-Year Non-COVID Revenues Rise 12 Percent
Premium

JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Illumina, Oxford Nanopore, Natera, More

Abbott Molecular HPV Test Nabs FDA Approval

Abbott PCR Test Gets FDA Approval as CDx for Servier's Tibsovo for Rare Blood Cancer

Abbott Q3 Diagnostics Revenues Fall 33 Percent on Lower COVID-19 Testing

In Brief This Week: DermTech, Cerca Biotech, Colossal Biosciences, Biocept, Abbott, More

Abbott Emphasizes Base Business Growth as Q2 Dx Revenues Drop 46 Percent

In Brief This Week: UC Berkeley, Biocept, Biocartis, Angle, Twist Bioscience, More

Abbott Alinity Sales up as Normal Hospital Purchasing Patterns Return; Dx Q1 Revs Down 49 Percent
Premium

As Pandemic Wanes, Firms That Rode COVID-19 Testing Wave Struggle for Solid Footing
Premium

In Brief This Week: Personalis, Biocartis, Opko Health, Berkeley Lights, More

In Brief This Week: Meridian Bioscience, SQI Diagnostics, Applied DNA, Abbott, Danaher, More

Abbott Q4 Diagnostics Revenues Fall 26 Percent on Declining COVID-19 Sales

JP Morgan Healthcare Conference, Day 2: Thermo Fisher, Agilent, Roche, Seer, More

Abbott Q3 Diagnostics Revenues Fall 6 Percent Due to COVID-19 Testing Decline
Premium

New Products Posted to GenomeWeb: Beckman Coulter, Helix, Objective Biotechnology, U of Washington

People in the News at NeoGenomics, ACMG, Seek Labs

Eric Green's Term as NHGRI Director Ends as Appointment Not Renewed by NIH

Revvity Expands Pact With Genomics England to Provide Sequencing Services for Newborn Study

In Brief This Week: Circular Genomics, Parse Biosciences, Flatiron Health, More

Abbott

2023 a 'Transition Year' for Abbott as Full-Year Non-COVID Revenues Rise 12 Percent Premium

Abbott Alinity Sales up as Normal Hospital Purchasing Patterns Return; Dx Q1 Revs Down 49 Percent Premium

As Pandemic Wanes, Firms That Rode COVID-19 Testing Wave Struggle for Solid Footing Premium

Abbott Q3 Diagnostics Revenues Fall 6 Percent Due to COVID-19 Testing Decline Premium

2023 a 'Transition Year' for Abbott as Full-Year Non-COVID Revenues Rise 12 Percent
Premium

Abbott Alinity Sales up as Normal Hospital Purchasing Patterns Return; Dx Q1 Revs Down 49 Percent
Premium

As Pandemic Wanes, Firms That Rode COVID-19 Testing Wave Struggle for Solid Footing
Premium

Abbott Q3 Diagnostics Revenues Fall 6 Percent Due to COVID-19 Testing Decline
Premium